Physician
Arh Mary Breckinridge Health Services, INC.
Arh Mary Breckinridge Health Services, INC. was paid $24.80M by Medicaid between Jul 2018 and Dec 2024, across 168 billing codes. Its largest line is 99284, emergency room visit (serious) — 25% of everything it billed.
33Billing provider infoARH MARY BRECKINRIDGE HEALTH SERVICES, INC.
MARTIN, KY 41649
MARTIN, KY 41649
33aNPI1306339460assigned 06/12/2018
33bProvider typeEmergency Medicine Physician
28Total paid$24.80M
24GClaims319,358
24DCodes billed168
24AFirst – last monthJul 2018 – Dec 2024
Compared with peers
Next to other Emergency Medicine Physician providers in Kentucky
Rank by total paid#3 of 91
Median peer was paid$34K
This provider vs. median727×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HARRIS, HOLLIE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,607 | $1.14M | |
| 2019 | 49,424 | $2.68M | |
| 2020 | 44,482 | $2.80M | |
| 2021 | 56,467 | $3.95M | |
| 2022 | 57,213 | $5.07M | |
| 2023 | 51,654 | $5.07M | |
| 2024incomplete | 39,511 | $4.09M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 25% | 11,356 | 9,260 | $6.09M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 9.1% | 2,622 | 2,244 | $2.25M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.0% | 17,423 | 15,202 | $1.72M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.9% | 3,474 | 2,054 | $1.70M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.8% | 1,103 | 1,003 | $1.43M |
| 80053 | Comprehensive metabolic panel | 3.7% | 22,729 | 17,087 | $927K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.9% | 1,930 | 1,580 | $725K |
| G0378 | Hospital observation service, per hour | 2.2% | 1,934 | 717 | $541K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.8% | 6,616 | 5,320 | $447K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.7% | 20,632 | 17,002 | $421K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.6% | 425 | 362 | $406K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.5% | 7,063 | 6,334 | $366K |
156 more codes
| 71045 | Radiologic examination, chest; single view | 1.4% | 5,569 | $355K |
| 36415 | Collection of venous blood by venipuncture | 1.4% | 41,462 | $341K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.3% | 5,602 | $333K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 3,711 | $326K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 5,109 | $297K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 3,583 | $264K |
| 87631 | 1.0% | 2,646 | $259K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.0% | 2,369 | $256K |
| 84484 | <1% | 4,841 | $236K | |
| 82607 | <1% | 4,177 | $226K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,181 | $225K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,680 | $220K |
| 80061 | Lipid panel | <1% | 6,130 | $215K |
| 87040 | <1% | 2,589 | $189K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,854 | $177K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,228 | $166K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,455 | $159K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,013 | $148K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,470 | $142K |
| 81001 | <1% | 9,364 | $136K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,496 | $129K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,121 | $121K |
| 83690 | <1% | 4,459 | $118K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,156 | $113K |
| 81025 | <1% | 3,290 | $105K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,050 | $102K |
| 74022 | <1% | 465 | $101K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,327 | $100K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,686 | $95K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,437 | $94K |
| 82746 | <1% | 1,375 | $89K | |
| 72100 | <1% | 904 | $83K | |
| 83735 | <1% | 6,594 | $81K | |
| 83605 | <1% | 2,279 | $80K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,685 | $80K |
| 73630 | <1% | 853 | $79K | |
| 83880 | <1% | 1,178 | $74K | |
| 72131 | <1% | 102 | $69K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 736 | $61K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 212 | $57K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 950 | $56K |
| 73610 | <1% | 546 | $56K | |
| 73030 | <1% | 666 | $53K | |
| 87186 | <1% | 1,239 | $46K | |
| 73562 | <1% | 536 | $44K | |
| 82150 | <1% | 1,964 | $43K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 799 | $43K |
| 73130 | <1% | 427 | $41K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 51 | $39K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 373 | $37K |
| 83540 | <1% | 1,247 | $37K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,451 | $30K |
| 82550 | <1% | 1,441 | $30K | |
| 93041 | <1% | 858 | $26K | |
| 74018 | <1% | 259 | $26K | |
| 85378 | <1% | 827 | $26K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,456 | $25K |
| 87076 | <1% | 1,074 | $25K | |
| 82553 | <1% | 798 | $24K | |
| 84439 | <1% | 641 | $22K | |
| 85027 | <1% | 1,404 | $21K | |
| 0100U | <1% | 330 | $20K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,596 | $18K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 692 | $18K |
| 87077 | <1% | 618 | $17K | |
| 85730 | <1% | 711 | $17K | |
| 85610 | <1% | 1,205 | $16K | |
| 85652 | <1% | 770 | $15K | |
| 74150 | <1% | 43 | $15K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 65 | $14K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 273 | $13K |
| 87070 | <1% | 743 | $13K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 118 | $12K |
| 87522 | Neg quan hep c or qual rna | <1% | 250 | $12K |
| 96376 | <1% | 364 | $12K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 644 | $12K |
| 86140 | <1% | 428 | $12K | |
| 73564 | <1% | 96 | $11K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 249 | $11K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 210 | $11K |
| 72040 | <1% | 173 | $10K | |
| 83550 | <1% | 291 | $10K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 13 | $9K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,477 | $9K |
| 80074 | <1% | 100 | $9K | |
| 86403 | <1% | 319 | $9K | |
| 94761 | <1% | 103 | $8K | |
| J3490 | Unclassified drugs | <1% | 193 | $8K |
| 87400 | <1% | 421 | $8K | |
| 87581 | <1% | 212 | $8K | |
| 82652 | <1% | 193 | $8K | |
| 87486 | <1% | 254 | $8K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 435 | $8K |
| 90715 | <1% | 155 | $8K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 605 | $7K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 18 | $7K |
| 82043 | <1% | 346 | $7K | |
| 82803 | <1% | 64 | $6K | |
| 87430 | <1% | 453 | $6K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 271 | $6K |
| 0002A | <1% | 303 | $5K | |
| 94664 | <1% | 231 | $5K | |
| 0001A | <1% | 355 | $5K | |
| 73110 | <1% | 40 | $4K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 233 | $4K |
| 81002 | <1% | 567 | $4K | |
| 80076 | <1% | 74 | $4K | |
| 84436 | <1% | 79 | $3K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 97 | $3K |
| 72072 | <1% | 31 | $3K | |
| 86038 | <1% | 126 | $3K | |
| 82728 | <1% | 53 | $3K | |
| 80047 | <1% | 62 | $3K | |
| 97161 | <1% | 70 | $3K | |
| 73590 | <1% | 33 | $2K | |
| 73090 | <1% | 26 | $2K | |
| 84425 | <1% | 29 | $2K | |
| 85379 | <1% | 52 | $2K | |
| 84153 | <1% | 41 | $2K | |
| 84403 | <1% | 52 | $1K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 83 | $1K |
| 73502 | <1% | 13 | $1K | |
| 81003 | <1% | 166 | $1K | |
| 76536 | <1% | 12 | $1K | |
| 12001 | <1% | 12 | $1K | |
| A9270 | Non-covered item or service | <1% | 115 | $1K |
| 84145 | <1% | 12 | $1K | |
| 84550 | <1% | 87 | $999.46 | |
| 88185 | <1% | 16 | $976.02 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 14 | $954.07 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 102 | $953.53 |
| 84480 | <1% | 17 | $789.53 | |
| 86308 | <1% | 41 | $785.53 | |
| 82962 | <1% | 54 | $773.71 | |
| 87280 | <1% | 23 | $762.68 | |
| 96368 | <1% | 14 | $739.94 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 20 | $518.77 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 170 | $507.26 |
| 84100 | <1% | 27 | $468.98 | |
| 82570 | <1% | 13 | $446.84 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 20 | $444.67 |
| 0012A | <1% | 29 | $437.20 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 16 | $404.86 |
| 85651 | <1% | 26 | $351.71 | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 21 | $334.02 |
| 84270 | <1% | 13 | $329.93 | |
| 84402 | <1% | 13 | $283.34 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 12 | $255.80 |
| 80143 | <1% | 25 | $241.60 | |
| 0011A | <1% | 28 | $227.78 | |
| J2704 | Injection, propofol, 10 mg | <1% | 16 | $201.56 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 193 | $196.83 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 79 | $80.63 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 13 | $21.80 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 15 | $1.34 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 21 | $0.01 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARRIS, HOLLIE (PRESIDENT AND CEO)
Parent organizationAPPALACHIAN REGIONAL HELATHCARE, INC.
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.